Max Financial

•

Emkay

Steady quarter; confident commentary on growth and margins

Life Insurance >

Result Update

November 12, 2025

CMP (Rs): 1,719 | TP (Rs): 1,900

Axis Max Life delivered steady performance in H1FY26, with VNB margin at 23.3% (+220bps YoY; Emkay: 22.5%) and APE at Rs41.8bn (+15% YoY; Emkay: Rs41.5bn), driving strong growth in VNB at 27%. The improvement in VNB margin was largely driven by a shift in the product mix toward non-par and protection products. While GST ITC losses are expected to have a gross impact of ~300-350bps on VNB margins, the management plans to mitigate the impact by 1) improving the product mix and structures, 2) negotiating with distributors and vendors, and 3) improving cost efficiency. Despite the GST ITC loss impact, the management reiterated its guidance on VNB margin at 24-25% and on APE growth at ~15-17% for FY26. While we keep our APE and VNB margin estimates broadly unchanged for FY26-28, we raise our Sep-26E TP by ~6% to Rs1,900 (Rs1,800 earlier), implying FY27E P/EV of 2.4x, owing to confident commentary on growth and margin over the medium term. We retain ADD on the stock.

Healthy VNB margin delivery drives strong VNB growth

During H1FY26, APE at Rs41.8bn grew ~15% and was largely in line with our estimated Rs41.5bn. H1 VNB margin at 23.3% (+220bps YoY) was higher than our estimate of 22.5%. The improvement in VNB margin was on account of a shift in the product mix toward non-par and protection products and some increase in product-level margins. Resultantly, VNB at Rs9.7bn grew at a strong 27% (a beat vs Emkay estimate of Rs9.3bn), largely driven by a beat on VNB margin. Embedded value at Rs269bn grew 15% YoY and was largely in line with our estimated Rs270.4bn, although impacted by GST ITC losses of Rs2.68bn (1.1% impact on opening EV) in the renewal book.

Limited impact from GST ITC losses; healthy growth and VNB margin outlook

While the gross impact on the VNB margin due to GST ITC loss is ~300-350bps, the management plans to mitigate the impact by tweaking the product structure (especially for ULIPs and Par, which remain more impacted), shifting the product mix toward high-margin products, negotiating with distributors on commission rates, and improving cost efficiencies. The management stated that the protection segment has seen strong traction, following the GST rate cut benefits, and expects it to continue ahead. Axis Bank channel saw significant improvement in its product mix, and the management remains confident of growth recovery in the channel in H2. The management reiterated its APE growth (~15-17%) and VNB margin (~24-25%) guidance for FY26 despite the short-term impact of GST ITC losses. The management continues to drive growth across proprietary and partnership channels, while maintaining a balanced product mix; it aims to grow 300-500bps above the industry growth rate over the next 5Y.

We revise up our Sep-26E TP to Rs1,900

Given the Q2 developments, we keep our FY26-28E APE and VNB margin broadly unchanged; however, we cut our FY26-28E PAT, owing to increased new business strain and the impact of GST ITC losses. Given the management's confident commentary on APE and VNB margin over the medium term, we increase our Sep-26E TP to Rs1,900 (from Rs1,800 earlier), implying FY27E P/EV of 2.4x.

Max Financial: Finan	ncial Snaps	shot			
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
GWP	295,290	332,226	381,695	440,294	507,956
APE	74,330	87,770	101,988	117,287	134,931
VNB	19,730	21,074	25,100	29,217	34,017
VNB margin (%)	26.5	24.0	24.6	24.9	25.2
APE growth (%)	19.0	18.1	16.2	15.0	15.0
VNB growth (%)	1.2	6.8	19.1	16.4	16.4
Adj. EPS (Rs)	9.9	9.5	7.6	10.6	12.8
EV	194,940	251,918	295,760	348,441	408,221
EVOP	32,850	37,304	43,842	52,682	60,947
Op. RoEV (%)	20.2	19.1	17.4	17.8	17.5
EVPS (INR)	452.0	This r 584 01t	is inte685.7	for Te 807.8 /	hite M946.4e
P/EV (x)	3.8	2.9	2.5	2.1	1.8
P/EVOP (x)	22.6	19.9	16.9	14.1	12.2

Source: Company, Emkay Research

Target Price – 12M	Sep-26
Change in TP (%)	5.6
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	10.5

Stock Data	MAXF IN
52-week High (Rs)	1,728
52-week Low (Rs)	950
Shares outstanding (mn)	345.1
Market-cap (Rs bn)	593
Market-cap (USD mn)	6,692
Net-debt, FY26E (Rs mn)	NA
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	920.4
ADTV-3M (USD mn)	10.4
Free float (%)	74.5
Nifty-50	25,875.8
INR/USD	88.6
Shareholding, Sep-25	
Promoters (%)	1.7
FPIs/MFs (%)	44.8/47.3

Price Performa	Price Performance					
(%)	1M	3M	12M			
Absolute	8.7	8.2	40.5			
Rel. to Nifty	6.2	2.4	29.7			



Avinash Singh

avinash.singh@emkayglobal.com +91-22-66121327

Mahek Shah mahek.shah@emkayglobal.com +91-22-66121218

Exhibit 1: MAX Financial - H1FY26 Financial Performance

(Rs bn)	H1FY26	H1FY25	% YoY	H1FY26E %	Variance Q	2FY26 (2FY25	% YoY Q	2FY26E %	Variance
Annualized Premium Equivalent (APE)	41.8	36.2	15.2	41.5	0.6	25.1	21.7	15.5	24.8	1.1
o/w Savings	33.5	30.0	11.6			20.6	18.4	12.4		
o/w Protection	8.3	6.2	32.7			4.4	3.3	33.2		
Protection (% of APE)	19.8	17.2	2.6ppt			17.7	15.3	2.3ppt		
Value of New Business	9.7	7.7	27.2	9.3	4.3	6.4	5.1	24.8	5.98	6.8
New Business margin (%)	23.3	21.1	2.2ppt	22.5	0.8ppts	25.5	23.6	1.9ppt	24.1	1.4ppts
Embedded Value	269.0	233.4	15.2	270.4	-0.5					
Operating RoEV (%)	16.3	16.8	-0.5ppt							
Total New Business Premium	59.9	51.0	17.5			34.6	30.2	14.7		
Renewal premium	95.0	80.4	18.2			56.3	47.2	19.3		
Gross written premium	154.9	131.4	17.9			90.9	77.4	17.5		
AUM	1,853	1,701	8.9	1,905	-2.7					
13 th month persistency (%)	85.0	87.0	-2.0ppt							
49 th month persistency (%)	58.0	67.0	-9.0ppt							
61st month persistency (%)	54.0	58.0	-4.0ppt							
Solvency ratio (%)	208	198	10.0ppt							

Source: Company, Emkay Research

Exhibit 2: MAX Financial - Appraisal-based valuation methodology

Parameter (Rs bn)	Value
FY25-39E APE CAGR	10.6%
FY25-39E VNB CAGR	11.1%
Terminal growth rate	5.0%
Cost of Equity	13.0%
FY26E EV	296
Present value of future new business	565
FY26E Appraisal value	860
Max Financial ownership in Max Life	80.0%
FY26E Fair value of Max Financials (10% Holdco discount)	619
No of shares	345.1
FV per share (Rs)	1,795
Sep-26E Target Price (Rs)	1,900

Source: Company, Emkay Research

Exhibit 3: MAX Financial – Implied valuation multiples

Target multiples on FY27 estimates	Rs1,900
Implied P/EV	2.4x
RoEV (%)	17.8
P/EVoP	15.6x
Implied FY27E VNB multiple	20.9x

Current price multiple on FY27 estimates	Rs1,719
P/EV	2.1x
RoEV (%)	17.8
P/EVOP	14.1x
Implied FY27E VNB multiple	15.3x

Source: Company, Emkay Research


Exhibit 4: Changes in estimates

(Rs bn)		FY26E			FY27E			FY28E	
	Old	Revised	% Change	Old	Revised	% Change	Old	Revised	% Change
APE	102.0	102.0	0.0	117.3	117.3	0.0	134.9	134.9	0.0
VNB	25.1	25.1	0.0	29.2	29.2	0.0	34.0	34.0	0.0
VNB margin (%)	24.6	24.6	0.0pts	24.9	24.9	0.0pts	25.2	25.2	0.0pts
Embedded Value	295.8	295.8	0.0	348.4	348.4	0.0	408.0	408.2	0.0
Consolidated EPS (Rs)	9.8	7.6	-23.0	12.3	10.6	-13.7	14.9	12.8	-13.9

Source: Company, Emkay Research


Story in charts

Exhibit 5: Axis Max Life has seen YoY reduction in the share of




Source: Company, Emkay Research

Exhibit 7: Axis Max Life's APE grew 15% during H1FY26




Source: Company, Emkay Research

Exhibit 9: Expense ratio has improved on a YoY basis




Source: Company, Emkay Research

Exhibit 6: The share of the Proprietary channel has seen slight increase




Source: Company, Emkay Research

Exhibit 8: Axis Max Life delivered a strong VNB margin of 23.3%




Source: Company, Emkay Research

Exhibit 10: Persistency ratio for the 49^{th} month and 61^{st} month dropped YoY




Source: Company, Emkay Research

Exhibit 11: We expect APE to grow 15-16% over FY26-28E




Source: Company, Emkay Research

Exhibit 13: We expect Axis Max Life to report EV of Rs408bn by FY28E




Source: Company, Emkay Research

Exhibit 12: VNB margin to see gradual improvement



Source: Company, Emkay Research

Exhibit 14: Expense ratio is expected to be stable over FY27-28E



Source: Company, Emkay Research

Earnings Conference Call Highlights

- The gross impact of GST ITC loss on VNB margin is estimated at 300–350bps on an annualized basis.
- The management aims to mitigate the impact through cost optimization, product restructuring, and renegotiation with distributors and vendors.
- The management reiterated its VNB margin guidance of 24-25% for FY26.
- Discussions with distributor/vendor partners are currently underway and are expected to be finalized ahead.
- ULIPs and Participating (Par) products are identified as structurally impacted, and the company is working with distributors to redesign these offerings.
- A 60bps impact on VNB margin has already been observed from business written post 22-Sep.
- New partnerships have significantly boosted revenue, with Max Life ranking first in three of its six partner banks. The Axis Bank channel grew around 7%, while Yes Bank achieved 14% growth, and several newer banca channels delivered over 100% growth.
- Axis Bank channel has undergone a major product mix shift under the ongoing Axis Transformation project, aimed at improving productivity and mix quality.
- The management expects stronger growth momentum in H2, while maintaining the counter share at Axis Bank at ~65–66%.
- MFSL's accounting PAT declined primarily due to INDAS adjustments. In addition, Max Life's PAT was impacted by GST ITC losses, while the remaining reduction in MFSL's PAT stemmed from mark-to-market (MTM) movements.
- The management is optimistic about growth prospects of the life insurance industry, with key focus areas including digitalization and operational efficiency. It expects to outperform industry growth by 300–500bps over the next five years. The full-year growth guidance remains at 15–17%, with stronger recovery anticipated in H2.
- The improvement in VNB margin was primarily driven by a favorable product mix shift. The company's investment strategy remains stable, limiting the impact from operating leverage, though some leverage benefits are seen in proprietary channels.
- If margins exceed ~25%, the management plans to reinvest in expanding and strengthening the distribution network.
- The company recorded ~34% growth in pure protection, with strong performance across channels and improved traction post-GST.
- Rider attachment currently stands at 37%, down from ~45% last year, though the management noted a recovery trend since Sep-25.
- Future protection growth is expected to be led by proprietary channels, as these products require longer sales cycles. The offline proprietary channels (Agency and Direct) continue to have a higher share of protection products in the overall mix.
- The company's dependence on the Axis Bank channel for Group Credit Life (GCL) stands at around 40%, with new partner additions contributing to overall growth. The counter share of GCL in the Axis Bank channel remains at ~60%. The management indicated that the Credit Life business is gaining momentum in H2.

Evhibit	1 E. May	Einancial	- Consolidated	Financial Summary	
EXHIDIL	TD: Max	rınancıaı	- Consolidated	rmanciai Summarv	

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Income statement					
Max Life Profit before Tax	3,749	4,484	3,903	5,364	6,437
Holding company expenses net of income	200	210	221	232	243
Profit before Tax	4,148	4,501	3,682	5,133	6,193
Tax expense	222	434	366	503	603
Profit after Tax	3,926	4,034	3,317	4,630	5,590
Minorities	525	762	704	967	1,161
Group Net Income	3,401	3,272	2,613	3,663	4,430
Balance Sheet					
Source of Funds					
Shareholders' Equity	38,659	52,745	55,358	59,021	63,450
Minorities	5,036	11,287	12,321	13,246	14,134
Financial Liabilities	1,575,165	1,823,992	1,795,131	2,045,506	2,335,920
Non-financial Liabilities	8,875	11,963	194,203	218,884	247,001
Total	1,627,735	1,899,987	2,057,013	2,336,657	2,660,505
Application of Funds					
Investments	1,593,587	1,862,509	1,874,739	2,136,218	2,439,510
Other Financial Assets	1,726	2,881	144,777	158,549	173,057
Cash and Bank balance	9,059	10,706	14,936	16,951	19,281
Non-financial Assets	23,363	23,891	22,561	24,939	28,656
Total	1,627,735	1,899,987	2,057,013	2,336,657	2,660,505
No of shares outstanding (mn)	345.1	345.1	345.1	345.1	345.1
Weighted average number of shares (mn)	345.1	345.1	345.1	345.1	345.1
Weighted average diluted shares (mn)	345.1	345.1	345.1	345.1	345.1

Source: Company, Emkay Research

Axis Max Life: Financials and Valuations

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Gross premium	295,290	332,226	381,695	440,294	507,956
Net premium	289,847	325,977	377,878	435,891	502,876
Investment income	170,875	131,358	127,319	154,508	176,264
Other income	77	844	0	0	(
Total revenue	460,800	458,179	505,197	590,400	679,140
Commission expense	23,983	31,449	36,456	41,617	47,510
Operating expense	40,861	45,140	53,348	60,361	69,637
Benefits paid (net)	133,212	170,283	195,158	220,432	251,170
Change in reserves	257,486	205,253	216,653	263,553	305,699
Total expenses	457,636	454,843	504,577	589,379	677,963
Surplus/Deficit	3,164	3,336	620	1,021	1,178
Trf from policyholders acct	2,612	2,777	620	1,021	1,17
Shareholders' results	1,136	1,707	3,283	4,343	5,25
PBT	3,749	4,484	3,903	5,364	6,43
Extraordinary items	-	-	-	-	
Tax expense	152	420	366	503	60
Minority interest	-	-	-	-	
Income from JV/Associates	0	0	0	0	(
Reported PAT	3,597	4,064	3,537	4,862	5,834
PAT growth (%)	(17.4)	13.0	(13.0)	37.4	20.0
Adjusted PAT	3,597	4,064	3,537	4,862	5,834
Diluted EPS (Rs)	0	0	0	0	(
Diluted EPS growth (%)	0	0	0	0	
DPS (Rs)	0	0	0	0	0.0
Dividend payout (%)	-	-	-	-	
Effective tax rate (%)	4.1	9.4	9.4	9.4	9.4
Shares outstanding (mn)	1,918	1,918	1,918	1,918	1,91

Source: Company, Emkay Research

Miscellaneous Metrics					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
APE	74,330	87,770	101,988	117,287	134,931
VNB	19,730	21,074	25,100	29,217	34,017
VNB margin (%)	26.5	24.0	24.6	24.9	25.2
APE growth (%)	19.0	18.1	16.2	15.0	15.0
VNB growth (%)	1.2	6.8	19.1	16.4	16.4
Operating ratios (%)					
NB commission/APE	26.3	-	-	-	-
Commissions/TWRP	9.3	10.6	10.6	10.5	10.4
Total exp ratio/TWRP	25.1	25.8	26.2	25.8	25.7
Conservation ratio	83.1	82.9	82.9	82.9	82.9
Solvency ratio	172.0	201.0	0	0	0
ROE	9.2	7.2	4.8	6.4	7.2
Historical metrics					
APE mix (%)	FY24	FY25	FY26E	FY27E	FY28E
A. Retail protection	8.0	10.0	0	0	0
B. Group protection	5.0	5.0	0	0	0
C. Savings - individual	-	-	-	-	-
Par	18.0	15.0	0	0	0
Non-Par	34.0	28.0	0	0	0
ULIP	35.0	42.0	0	0	0
D. Group Savings	0	0	0	0	0
Persistency ratios (%)	-	-	-	-	-
13th Month	87.0	88.0	0	0	0
49th Month	66.0	57.0	0	0	0

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	19,188	20,614	20,614	20,614	20,614
Reserves & Surplus	20,184	39,784	43,321	48,182	52,849
Net worth	39,372	60,397	63,935	68,796	73,463
Borrowings	4,960	9,960	9,960	9,960	9,960
Policy liabilities	973,550	1,142,915	1,290,926	1,470,978	1,679,822
Provision for linked liab	387,991	423,591	478,447	545,178	622,581
FFA	38,727	42,470	43,090	44,111	45,288
Current liab and provison	36,183	48,047	56,632	67,116	78,769
Total liabilities & Equity	1,538,216	1,776,671	1,997,482	2,266,917	2,578,461
Shareholders' Investment	58,484	90,932	96,184	103,402	110,331
Policyholder Investment	1,008,078	1,182,110	1,335,197	1,521,424	1,737,430
Assets to cover linked liab.	441,793	477,681	539,542	614,794	702,080
Current assets	51,286	56,507	63,529	72,099	82,007
Total Assets	1,538,216	1,776,671	1,997,482	2,266,917	2,578,461
BV/Share (INR)	112.0	152.8	160.4	171.0	183.9
EV/share (INR)	452.0	584.1	685.7	807.8	946.4
EVOP/share (INR)	76.2	86.5	101.6	122.1	141.3
Embedded value	194,940	251,918	295,760	348,441	408,221
ANW	39,260	60,521	64,058	68,920	73,587
VIF	155,680	191,397	231,701	279,521	334,635
VIF share in EV (%)	79.9	76.0	78.3	80.2	82.0
Total AUM	1,508,355	1,750,723	1,970,923	2,239,619	2,549,841
Investment yield (%)	12.8	8.4	7.2	7.7	7.7
Yield on PH funds (%)	13.0	8.4	7.2	7.7	7.7
Yield on SH funds (%)	6.9	7.8	7.5	7.5	7.5

Source: Company, Emkay Research

Valuation & key ratios	;				
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	174.4	181.3	227.0	162.0	133.9
P/B (x)	15.3	11.2	10.7	10.1	9.3
P/EV (x)	3.8	2.9	2.5	2.1	1.8
P/EVOP (x)	22.6	19.9	16.9	14.1	12.2
Implied P/VNB (x)	29.3	25.9	19.5	15.3	11.6
Dividend yield (%)	0	0	0	0	0.0
EV account and RoEV					
Opening EV	162,630	194,940	251,918	295,760	348,441
Premium unwind	13,690	16,180	20,405	23,365	26,830
VNB	19,730	21,074	25,100	29,217	34,017
Operating variance	(570)	50	(1,663)	100	100
EVOP	32,850	37,304	43,842	52,682	60,947
Investment variance	(540)	3,560	0	0	0
Capital movement	0	16,120	0	0	(1,167)
Other changes	0	0	0	0	0
Closing EV	194,940	251,918	295,760	348,441	408,221
Change in EV	32,310	56,978	43,842	52,682	59,780
RoEV (%)	19.9	21.0	17.4	17.8	17.5
Operating RoEV (%)	20.2	19.1	17.4	17.8	17.5
EVOP growth (%)	4.9	13.6	17.5	20.2	15.7
EV growth (%)	19.9	29.2	17.4	17.8	17.2
Core operating RoEV (%)	20.2	19.1	17.4	17.8	17.5
Unwind rate (%)	8.4	8.3	8.1	7.9	7.7
VNB-to-opening EV (%)	12.1	10.8	10.0	9.9	9.8

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
10-Nov-25	1,619	1,800	Add	Avinash Singh
09-Oct-25	1,596	1,800	Add	Avinash Singh
06-Oct-25	1,605	1,800	Add	Avinash Singh
23-Sep-25	1,585	1,800	Add	Avinash Singh
09-Sep-25	1,598	1,800	Add	Avinash Singh
08-Sep-25	1,584	1,800	Add	Avinash Singh
21-Aug-25	1,659	1,800	Add	Avinash Singh
19-Aug-25	1,637	1,800	Add	Avinash Singh
08-Aug-25	1,552	1,800	Add	Avinash Singh
11-Jul-25	1,567	1,800	Add	Avinash Singh
07-Jul-25	1,569	1,800	Add	Avinash Singh
09-Jun-25	1,525	1,500	Add	Avinash Singh
14-May-25	1,338	1,500	Add	Avinash Singh
14-May-25	1,338	1,350	Add	Avinash Singh
09-May-25	1,268	1,350	Add	Avinash Singh
24-Apr-25	1,248	1,350	Add	Avinash Singh
03-Apr-25	1,148	1,350	Add	Avinash Singh
12-Feb-25	1,091	1,350	Add	Avinash Singh
05-Feb-25	1,119	1,350	Add	Avinash Singh
12-Jan-25	1,078	1,350	Add	Avinash Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 12, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 12, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 12, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

	· J ·····
Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.